Sydney, Feb 20, 2026, 18:22 AEDT — Market has closed for the day.
- Pro Medicus slipped 2.1% to finish at A$126.51, bouncing between A$123.36 and A$129.49 during the session.
- Attention shifts to next week’s ex-dividend date, with some watching to see if volatility cools off after the results.
- The stock’s valuation remains lofty, so there isn’t much cushion if the company stumbles on timing.
Pro Medicus Ltd (ASX:PME) shares dropped 2.1% Friday, finishing the session at A$126.51 after a previous close of A$129.16. Shares fluctuated between A$123.36 and A$129.49 during the day, leaving the medical imaging software company with a market cap near A$13.2 billion. (Google)
This shift is grabbing attention as investors keep recalibrating the value of high-growth stocks in the wake of a rough earnings stretch. Pro Medicus stands out as a key gauge in this process. Looking ahead, a dividend cutoff is on the calendar next week, along with the usual burst of broker updates.
There wasn’t much support from the broader market. The S&P/ASX 200 slipped 0.05% on Friday, with earnings news driving uneven swings across sectors. (Market Index)
Pro Medicus notched a 3.6% gain on Thursday, adding to Tuesday’s sharp 7.3% rally, according to data from Intelligent Investor. (Intelligent Investor)
In its latest results, the company posted first-half revenue from customer contracts at A$124.8 million, with statutory profit for the six months to Dec. 31 coming in at A$171.2 million. The interim report attributed A$149.0 million of that profit to a fair-value gain recognized under “other financial assets”. (Company Announcements)
Sam Hupert, the chief executive, dismissed concerns about fresh trouble in the half-year results. “There wasn’t anything that happened in a negative sense at all,” he told Capital Brief. (Capital Brief)
Some analysts zeroed in on timing rather than demand. RBC Capital Markets’ Garry Sherriff flagged a 2% miss on revenue consensus and a 10% shortfall in EBIT — earnings before interest and tax — which he chalked up to “contract phasing difficulties.” Over at Citi, the focus landed on a hefty one-off related to the group’s holding in 4D Medical, according to Capital Brief. (Capital Brief)
Dividend action is up next. MarketIndex data points to Pro Medicus going ex-dividend on Feb. 26, marking the deadline for investors hoping to qualify for the next payout. (Market Index)
Pro Medicus, known for its Visage 7 radiology imaging software, pulls the bulk of its revenue from North America, according to Morningstar data. That foothold has powered expansion, though it leaves the company’s numbers sensitive to U.S. contract rollouts. (Morningstar)
The risk here is clear enough: with the stock priced at a hefty multiple, even minor delays in rollout can sting. Shares tumbled almost 20% following the half-year update, despite what Investing.com called a “record” first-half showing—underscoring just how little patience there is in this market. (Investing.com)
